Journal of Mosquito Research 2024, Vol.14, No.1, 18-25 http://emtoscipublisher.com/index.php/jmr 20 Table 1 Assignment of each cynomolgus macaque to low dose (1 infected mosquito) or high dose (10 infected mosquitoes) of DENV, or high dose (15 infected mosquitoes) of ZIKV, or control (10 uninfected mosquitoes) treatments and subsequent viremia, transmission to mosquitoes, and neutralizing antibody response Figure 2 provides a comprehensive analysis of the effects of treatment with Dengue virus serotype 2 (DENV-2) and Zika virus (ZIKV) on rhesus monkeys and squirrel monkeys. The average peak titers and their 80% plaque reduction neutralization titers (PRNT80) for the rhesus monkeys show that ZIKV has stronger replicative ability than DENV-2. Analysis of squirrel monkeys also revealed similar results, with higher average peak titers for ZIKV and lower average PRNT80 against ZIKV, suggesting that ZIKV may induce a stronger immune response. Moreover, early natural killer (NK) cell percentages were negatively correlated with PRNT80 values, particularly in monkeys infected with DENV-2, and early NK cell percentages were also negatively correlated with peak viremia and duration of viremia for ZIKV, revealing the role of host immune cells in the clearance of the virus. Figure 2 Effect of treatments on peak virus titer, 80% plaque reduction neutralization titer (PRNT80), and natural killer (NK) cells, and relationships among them, for dengue virus serotype 2 (DENV-2, in green) and Zika virus (ZIKV, in blue); values for individual animals shown as points
RkJQdWJsaXNoZXIy MjQ4ODY0NQ==